New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
14:19 EDTCTRX, CICatamaran weakness a buying opportunity, says Cowen
Cowen attributes the weakness in shares of Catamaran (CTRX) to concerns over the company's relationship with Cigna (CI) should Cigna decide to keep its PBM. Cowen always expected Cigna to keep its PBM, and thinks the market is incorrectly assuming that Cigna's relationship with Catamaran will dissolve if that were to be the case. Cowen thinks the market is misunderstanding the services that Catamaran currently provides to Cigna and recommends buying the stock on today's pullback.
News For CTRX;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
10:01 EDTCIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:40 EDTCICigna downgraded at Sterne Agee
Subscribe for More Information
05:49 EDTCICigna downgraded to Neutral from Buy at Sterne Agee
Subscribe for More Information
October 13, 2014
07:39 EDTCTRXPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
October 9, 2014
09:12 EDTCTRXCatamaran acquisition in-line with expectations, says Leerink
Subscribe for More Information
07:37 EDTCTRXCatamaran acquisition likely to be well-received, says Oppenheimer
Subscribe for More Information
October 8, 2014
16:34 EDTCTRXCatamaran to acquire Salveo Specialty Pharmacy for $260M in cash
Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.
October 7, 2014
07:12 EDTCICigna price target raised to $110 from $95 at JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use